'Cv events' presentation slideshows

Anemia and Cardiovascular Disease: The Good, The Bad, The Ugly

1.51k views • 89 slides

TMA DoD Pharmacoeconomic Center Fort Sam Houston, TX

TMA DoD Pharmacoeconomic Center Fort Sam Houston, TX. MTF Quarterly Webcast. LTC Stacia Spridgen Director, DoD Pharmacoeconomic Center. Introduction. Greetings from the PEC Purpose of the Quarterly MTF Webcast DCO Ground Rules Type questions into DCO system Put on mute, not on hold

929 views • 71 slides

How to Cure Type 2 Diabetes

950 views • 67 slides

COX-2 & 2x: Improved Safety?

907 views • 60 slides

Hypertension 2017

Putting the Evidence into Practice. Hypertension 2017. Disclosures. Relationships with commercial interests : Grants/ Research Support: Speakers Bureau/ Honoraria : Consulting Fees : Data Safety and Monitoring:. Disclosure of Commercial Support.

787 views • 58 slides

Treatment of Hypertension in the Elderly: A Major Challenge

Treatment of Hypertension in the Elderly: A Major Challenge. Thomas G Pickering MD, D Phil Behavioral Cardiovascular Health and Hypertension Program Columbia Presbyterian Hospital. Treating older adults: Updates and Practical Approaches. Risks associated with high BP JNC 7 Guidelines

1.24k views • 48 slides

Peripheral Arterial Disease of the Lower Limb Diagnosis and Medical therapy

338 views • 31 slides

NCEP ATP III Cholesterol Guidelines and Updates

NCEP ATP III Cholesterol Guidelines and Updates. Anoop Agrawal, M.D. Med-Peds Continuity Clinic Baylor College of Medicine. Background. Adult Treatment Panel of the National Cholesterol Education Program issued their third guideline for cholesterol management in 2001 - known as ATP III .

850 views • 26 slides

Stefano Genovese Diabetologia e Malattie Metaboliche

437 views • 26 slides

Conflict of Interest Statement:

THE LIPID PANEL What are we missing? Robert St. Amant, MD, FAAFP Diplomate, American Board of Clinical Lipidology Baton Rouge General Medical Director, Lipid Center Womack Heart Center. Conflict of Interest Statement:. Speakers Bureau for the following companies: Abbott Laboratories

356 views • 25 slides

Lipoprotein- associated Phospholipase A 2 (Lp-PLA 2 ) activity: Background

STABILITY St abilization of A therosclerotic plaque B y Initiation of darap L ad I b T herap Y Harvey D White on behalf of The STABILITY Investigators. Lipoprotein- associated Phospholipase A 2 (Lp-PLA 2 ) activity: Background. native LDL carrier of Lp-PLA 2. Lp-PLA 2. Leukocyte.

776 views • 24 slides

The Sleep Apnea cardioVascular Endpoints study (SAVE )

The Sleep Apnea cardioVascular Endpoints study (SAVE ). R. Doug McEvoy Professor of Medicine , Adelaide Institute for Sleep Health Flinders University , AUSTRALIA doug.mcevoy@flinders.edu.au

369 views • 21 slides

Chronic Kidney Disease

543 views • 19 slides

Hisao Ogawa 1 , Shokei Kim-Mitsuyama 2 , Tomio Jinnouchi 3 , Hideaki Jinnouchi 3 , Kunihiko Matsui 4 and Kikuo Arakawa

Effect of High-dose Angiotensin II Receptor Blocker (ARB) Monotherapy versus ARB plus Calcium Channel Blocker Combination on Cardiovascular Events in Japanese Elderly High-risk Hypertensive Patients (OSCAR): a Randomized Trial.

617 views • 18 slides

Hisao Ogawa 1 , Shokei Kim-Mitsuyama 2 , Tomio Jinnouchi 3 , Hideaki Jinnouchi 3 , Kunihiko Matsui 4 and Kikuo Arakawa

Effect of High-dose Angiotensin II Receptor Blocker (ARB) Monotherapy versus ARB plus Calcium Channel Blocker Combination on Cardiovascular Events in Japanese Elderly High-risk Hypertensive Patients (OSCAR): a Randomized Trial.

362 views • 18 slides

AF tips

AF tips. Rate control. Goals of rate control: # <110 (or better <100) at rest is an acceptable goal if symptoms controlled with such a lenient rate and if LV function is normal (RACE II trial)

289 views • 13 slides

Atorvastatin in Type 2 diabetics on dialysis: 4D Study

Atorvastatin in Type 2 diabetics on dialysis: 4D Study. 1255 T2DM patients on dialysis for 8.3 mo; 29% with prior MI or revascularization or CHD; 35% CHF; 45% PAD Baseline lipids: LDL-C 3.2 mmol /L;TG 3.0 mmol/L Atorva 20mg vs Pbo x 4 yrs; ? LDL-C: 1 mmol/L. 60.

345 views • 6 slides

Percent of Patients Achieving Target Level at 30 Days

Achieved Levels of On-Treatment Reactivity (30 Days): Stratified by Randomization Treatment Arm. Insufficient pharmacodynamic response may have contributed to the lack of observed clinical effect in the GRAVITAS trial. 100. Standard Dose High Dose. 80. 60.1. 60.

113 views • 2 slides

Major adverse CV events per quartile of percent atheroma volume (PAV)

Major adverse CV events per quartile of percent atheroma volume (PAV). Baseline PAV quartile 1: 14.78-30.73 quartile 2: 30.80-36.09 quartile 3: 36.12-41.74 quartile 4: 41.78-68.75 . 12. 10. 8. Cumulative incidence MACE (%). 6. 4. 2. month. 0. 3. 6. 9. 12. 15. 18.

229 views • 1 slides

Major adverse CV events per quartile of percent atheroma volume (PAV)

Baseline PAV quartile 1: 14.78-30.73 quartile 2: 30.80-36.09 quartile 3: 36.12-41.74 quartile 4: 41.78-68.75 . Major adverse CV events per quartile of percent atheroma volume (PAV). 12. 10. 8. Cumulative incidence MACE (%). 6. 4. 2. month. 0. 3. 6. 9. 12. 15. 18.

244 views • 1 slides